SciClone Pharmaceuticals Inc. (NASDAQ: SCLN) has filed to raise capital, some for the company and some for its existing shareholders. The filing with the SEC includes the sale of any combination of common stock, preferred stock, debt, warrants and/or units.
As noted in the filing:
We may from time to time in one or more offerings offer and sell up to $100 million aggregate dollar amount of common stock, preferred stock, debt securities, warrants to purchase common stock or preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. We will provide the specific terms for each of these securities in supplements to this prospectus. In addition, the selling stockholders may also offer and sell, from time to time, up to 10,000,000 share of common stock.
SciClone will not receive any of the proceeds from the sale of common stock by the selling stockholders.
You may recall that we recently noted how SciClone halted the development of its mucositis drug.
JON C. OGG